Dossier
clinicaltrials
trial early
Decitabine in Treating Patients With Myelofibrosis
Key claim: A phase II trial is evaluating the safety and efficacy of decitabine, a DNA-hypomethylating agent, in patients with advanced myelofibrosis lacking standard therapy.
Abstract
This phase II trial studies the side effects and how well decitabine works in treating patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar tissue) in the bone marrow that is advanced and for which there is no standard therapy. Decitabine may block the actions of some proteins that are responsible for turning certain genes off in various cancers including myelofibrosis.
Why this matters
A phase II trial is evaluating the safety and efficacy of decitabine, a DNA-hypomethylating agent, in patients with advanced myelofibrosis lacking standard therapy.